Leerink Partners Maintains Outperform on BlossomHill Therapeutics, Raises Price Target to $40

Benzinga Newsdesk www.benzinga.com Positive 90.6%

Neg 0% Neu 0% Pos 90.6%

Leerink Partners maintains BlossomHill Therapeutics (NASDAQ:BLSM) with a Outperform and raises the price target from $36 to $40.